{
    "clinical_study": {
        "@rank": "112786", 
        "acronym": "DOMS", 
        "arm_group": [
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "2 capsules identical to comparator, 3 times daily on Day 1 and Day 2.  On Day 3 only one dose will be taken. The intervention is Acetaminophen 1000mg."
            }, 
            {
                "arm_group_label": "Ibuprofen", 
                "arm_group_type": "Active Comparator", 
                "description": "2oomg capsules (400 mg per dose), 3 times daily on Day 1 and Day 2.  On Day 3 only one dose will be taken. The intervention is Acetaminophen 1000mg."
            }
        ], 
        "brief_summary": {
            "textblock": "The hypotheses to be tested are: Efficacy: Ibuprofen will be more effective than the Placebo\n      in relieving muscle pain/soreness over 48 hour post-dosing with study medication.  Safety:\n      There will be no or minimal increased incidence of adverse events (AEs) with Ibuprofen\n      versus and both will be well tolerated."
        }, 
        "brief_title": "A Study Comparing the Efficacy and Safety of Orally Administered Ibuprofen and Placebo in Delayed Onset Muscle Soreness", 
        "condition": "Delayed Onset Muscle Soreness", 
        "condition_browse": {
            "mesh_term": [
                "Pain", 
                "Muscular Diseases"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  are male or female, 18-55 years of age\n\n          -  are a sexually active female of childbearing potential willing to use a medically\n             acceptable form of birth control throughout the study and for 30 days following the\n             end of study participation\n\n          -  have a history of experiencing muscle soreness after moderately strenuous exercise\n\n          -  are in good general health, with a BMI less than or equal to 30, and able to perform\n             the exercise regimen\n\n          -  are able to read, comprehend, and sign the informed consent form\n\n          -  develop muscle pain/soreness within 24-48 hours of the end of the exercise regimen\n             and have a baseline muscle pain/soreness with movement of greater than or equal to 5\n             on the NRS (numerical rating scale) and at least \"moderate\" on the categorical scale\n\n        Exclusion Criteria:\n\n          -  regularly works out or exercises the upper extremities with weights or gym equipment\n             during the past 6 months\n\n          -  works in an occupation that requires regular heavy lifting or involvement of the\n             upper extremities (eg: mover, construction workers)\n\n          -  allergy or intolerance to any non-steroidal anti-inflammatory drug (NSAID), aspirin\n             or acetaminophen\n\n          -  the presence of any medical condition (eg: history of bleeding ulcers or current\n             peptic ulcer disease) that would preclude the subject from safely participating in\n             the study'\n\n          -  any form of arthritis that requires prescription or over-the-counter (OTC)treatment\n             pregnant or lactating female\n\n          -  current habituation or history of chronic use of analgesic or drugs or severe chronic\n             pain problems that do not respond to OTC medication and/or requires a prescription\n             analgesic\n\n          -  currently on chronic NSAID therapy for any reason\n\n          -  current or recent history of drug or alcohol abuse\n\n          -  has taken an analgesic medication within 5 half lives of performing the exercise\n             regimen during the run-in period or completing the baseline assessment\n\n          -  has donated blood within the past 30 days\n\n          -  is unable to swallow whole or large tablets or capsules\n\n          -  is unable/unwilling to remain at the study center for the 6 hour inpatient\n             observation period.\n\n          -  participation in an investigational study within the past 30 days of screening\n\n          -  prior participation in this trial\n\n          -  site employee or close relative of a site employee directly involved in the conduct\n             or the study or is an employee or close relative of the study doctor."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "55 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "60", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "April 6, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02113566", 
            "org_study_id": "JBR-001"
        }, 
        "intervention": {
            "arm_group_label": [
                "Placebo", 
                "Ibuprofen"
            ], 
            "description": "Subjects who require rescue medication between hours 4 and 6 will be allowed to take Dose 2 of the study medication.  If the subject chooses to take a rescue analgesic (acetaminophen 1000mg), they will be considered a treatment failure. This intervention will be use for the placebo and Ibuprofen arm.", 
            "intervention_name": "Acetaminophen 1000mg", 
            "intervention_type": "Drug", 
            "other_name": "Tylenol"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Acetaminophen", 
                "Ibuprofen"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Delayed onset muscle soreness", 
            "DOMS"
        ], 
        "lastchanged_date": "April 10, 2014", 
        "location": {
            "contact": {
                "email": "droberts@jbrutah.com", 
                "last_name": "Denise Roberts, RN", 
                "phone": "801-261-2000"
            }, 
            "contact_backup": {
                "email": "sseely@jbrutah.com", 
                "last_name": "Shana Seely, RN", 
                "phone": "801-261-2000"
            }, 
            "facility": {
                "address": {
                    "city": "Salt Lake City", 
                    "country": "United States", 
                    "state": "Utah", 
                    "zip": "84124"
                }, 
                "name": "Jean Brown Research"
            }, 
            "investigator": {
                "last_name": "Derek Muse, MD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Double-Blind, Repeat-Dose, Parallel Group Study Comparing the Efficacy and Safety of Orally Administered Ibuprofen and Placebo in Delayed Onset Muscle Soreness.", 
        "overall_contact": {
            "email": "droberts@jbrutah.com", 
            "last_name": "Denise Roberts, RN", 
            "phone": "801-261-2000"
        }, 
        "overall_contact_backup": {
            "email": "hkieffer@jbrutah.com", 
            "last_name": "Heather Kieffer, RN", 
            "phone": "801-261-2000"
        }, 
        "overall_official": {
            "affiliation": "Jean Brown Research", 
            "last_name": "Derek Muse, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "July 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "The primary efficacy parameter is muscle pain/soreness with movement at 48 hours (SPID 0-48)", 
            "measure": "SPID (Sum Pain Intensity Difference)", 
            "safety_issue": "No", 
            "time_frame": "0-48 hours"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02113566"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Jean Brown Research", 
            "investigator_full_name": "Derek Muse", 
            "investigator_title": "Derek Muse, MD", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "measure": "spontaneous muscle pain/soreness", 
                "safety_issue": "No", 
                "time_frame": "0-48 hours"
            }, 
            {
                "measure": "Muscle stiffness with movement", 
                "safety_issue": "No", 
                "time_frame": "0-48 hours"
            }, 
            {
                "measure": "Overall evaluation measures", 
                "safety_issue": "No", 
                "time_frame": "0-48 hours"
            }
        ], 
        "source": "Jean Brown Research", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Jean Brown Research", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "February 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}